Results 21 to 30 of about 176,389 (357)
Frontiers in Immunology, 2023 BackgroundThe disease burden caused by chronic hepatitis B virus (HBV) infection is still heavy, and the current treatment scheme has not achieved a complete cure. Changes in natural and adaptive immunity usually accompany chronic HBV infection.
Zilong Wang +7 more
doaj +1 more source
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Nature reviews: Gastroenterology & hepatology, 2020 One quarter of the global population is estimated to have nonalcoholic fatty liver disease (NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by up to 56% in the next 10 years.
Daniel Q. Huang, H. El-Serag, R. Loomba
semanticscholar +1 more source
Hepatology Communications, 2022 Metabolic‐associated fatty liver disease (MAFLD) is a series of liver diseases based on liver steatosis and metabolic disorders. Steatosis, as the core factor in MAFLD diagnosis, and fibrosis, as the major determinant of adverse outcomes of MAFLD, need ...
Xiaoxiao Wang +7 more
doaj +1 more source
Current management of NAFLD [PDF]
Medicine and Pharmacy Reports, 2016 Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. It affects about 1 billion individuals worldwide. While people with simple steatosis have no higher risk of death than the general population, people with non-alcoholic steatohepatitis are at increased risk of death compared to general ...
MUNTEANU, MIHAI ALEXANDRU +2 more
openaire +2 more sources
BMC Endocrine Disorders, 2022 Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public health.
S. Pouwels +9 more
semanticscholar +1 more source
Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC
Hepatology, EarlyView., 2022 Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu +11 more
wiley +1 more source
NAFLD: Mechanisms, Treatments, and Biomarkers
Biomolecules, 2022 Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver disease (MAFLD), is one of the most common causes of liver diseases worldwide. NAFLD is growing in parallel with the obesity epidemic.
F. Nassir
semanticscholar +1 more source
Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy [PDF]
, 2021 Non-alcoholic fatty liver disease (NAFLD) is poised to dominate the landscape of clinical hepatology in the 21st century. Its complex, interdependent aetiologies, non-linear disease progression and uncertain natural history have presented great ...
Aithal, Guruprasad P. +5 more
core +1 more source
Relationship between NAFLD and coronary artery disease: A Mendelian randomization study
Hepatology, EarlyView., 2022 Abstract Background and Aims There is an ongoing debate on whether NAFLD is an active contributor or an innocent bystander in the pathogenesis of coronary artery disease (CAD). The aim of the present study was to assess the causal relationship between NAFLD and CAD.
Zhewen Ren +4 more
wiley +1 more source
Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile
Annals of Hepatology, 2011 Background. The epidemiology and clinical characteristics of nonalcoholic fatty liver disease (NAFLD) in South America are not well known. Brazil is a largest country in this part of the world and the present study aimed to contribute with this ...
Helma P. Cotrim +15 more
doaj +1 more source